Quantitative Analysis of Carbonic Anhydrase IX Uncovers Hypoxia-Related Functional Differences in Classical Hodgkin Lymphoma Subtypes
Open Access
- 15 July 2019
- journal article
- research article
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 20 (14) , 3463
Abstract
Upregulation of carbonic anhydrase IX (CAIX) was found to be associated with unfavorable prognosis and resistance to treatment in a broad spectrum of malignancies, recently also in classical Hodgkin’s lymphoma (cHL). As demonstrated, variable CAIX expression in a significant number of cHL cases was associated with poor treatment response. The current study focused on the quantification CAIX immunopositivity and its relative expression compared to the total CD30+ neoplastic pool using digital image analysis. One hundred and one lymph node samples featuring cHL histology were analyzed for both CD30 and CAIX by immunohistochemistry. Whole histological slides were scanned and immunopositivity was determined as the histoscore (H-score) using the DensitoQuant software module (3DHistech Kft., Budapest, Hungary). CAIX positivity was observed in the HRS-cells of 56/101 cases (55.44%) and frequently observed in the proximity of necrotic foci. CAIX H-scores were highly variable (range: 2.16–90.36, mean 18.7 ± 18.8). Individual CAIX values were independent of the much higher CD30 values (range 3.46–151.3, mean 52.37 ± 30.74). The CAIX/CD30 index proved to be the highest in the aggressive lymphocyte-depleted (LD) subtype (CAIX/CD30: 0.876). The CAIX expression and the CAIX/CD30 relative index can be precisely determined by image analysis, and values reflect the extent of a tumor mass undergoing hypoxic-stress-related adaptation in the most aggressive forms of cHL.Keywords
This publication has 24 references indexed in Scilit:
- American Registry of Pathology Expert Opinions: Immunohistochemical evaluation of classic Hodgkin lymphomaAnnals of Diagnostic Pathology, 2019
- Hodgkin lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-upAnnals of Oncology, 2018
- Understanding CD30 biology and therapeutic targeting: a historical perspective providing insight into future directionsBlood Cancer Journal, 2017
- The 2016 revision of the World Health Organization classification of lymphoid neoplasmsBlood, 2016
- Carbonic anhydrase IX, a hypoxia-induced catalytic component of the pH regulating machinery in tumorsFrontiers in Physiology, 2014
- HIF-1 mediates metabolic responses to intratumoral hypoxia and oncogenic mutationsJournal of Clinical Investigation, 2013
- Histological expression of angiogenic factors: VEGF, PDGFRα, and HIF-1α in Hodgkin lymphomaPathology - Research and Practice, 2009
- CD30: expression and function in health and diseaseSeminars in Immunology, 1998
- CD30 antigen, a marker for Hodgkin's lymphoma, is a receptor whose ligand defines an emerging family of cytokines with homology to TNFCell, 1993
- Production of a monoclonal antibody specific for Hodgkin and Sternberg–Reed cells of Hodgkin's disease and a subset of normal lymphoid cellsNature, 1982